276 results on '"Cipolli, M."'
Search Results
2. P339 Maintenance of nutritional parameters improvements over two years of elexacaftor/tezacaftor/ivacaftor (ETI) treatment according to severity of cystic fibrosis (CF) pulmonary disease
3. P081 Comparative analysis of CFTR modulators: unravelling the impact on radiological and clinical outcomes
4. P063 ELX/TEZ/IVA has beneficial effects on clinical outcomes and quality of life in people with cystic fibrosis in the real-world TRAJECTORY study
5. P106 Monitoring the adverse drug reactions after elexacaftor/tezacaftor/ivacaftor therapy in the cystic fibrosis cohort
6. WS17.06 Two years of elezacaftor/tezacaftor/ivacaftor treatment show only a partial anti-inflammatory effect in patients with cystic fibrosis
7. P064 Improved quality of life in cystic fibrosis patients observed up to 36 months after starting elexacaftor/tezacaftor/ivacaftor treatment
8. 192 Unraveling the dark side of cystic fibrosis inflammation: cellular senescence
9. EPS5.09 Changes in nutritional status and muscular strength in adult patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)
10. 579 Integrin activation in monocytes as a novel potential test for cystic fibrosis transmembrane conductance regulator–targeted compounds in cystic fibrosis
11. 601 Effects of different combinations of CFTR targeted drugs on CFTR dependent sweating in people with cystic fibrosis
12. 534 COVID-19 in people with cystic fibrosis and the general population: Severity and virus-host cell interactions
13. 509 Cystic fibrosis transmembrane conductance regulator positively regulates angiotensin-converting enzyme 2 expression and SARS-CoV-2 viral entry into airway epithelial cells: Implications for patients with cystic fibrosis
14. Elexacaftor-tezacaftor-ivacaftor (ETI) treatment improves Lung Clearance Index (LCI) in patients with Cystic Fibrosis (CF) independently from baseline respiratory function
15. Respiratory outcomes at 6 months follow up after SARS-Cov-2 infection in people with cystic fibrosis
16. P026 Theratyping of the CFTR variant G85E in trans with the complex allele A1006E+V562I using rectal organoids
17. P159 Modifications of anthropometric parameters and body composition after Kaftrio® in a group of adolescents and young adults
18. P019 Monocyte integrin activation as a CFTR-targeted drugs evaluation test in cystic fibrosis patients: preliminary analysis
19. P054 Severity of COVID-19 infection in cystic fibrosis patients compared to the general population
20. ePS4.07 COVID-19 early vaccination campaign in Italian cystic fibrosis (CF) patients: the experience of the Italian Society for the Study of Cystic Fibrosis (SIFC)
21. MTOR and STAT3 pathway hyper-activation is associated with elevated interleukin-6 levels in patients with shwachman-diamond syndrome: Further evidence of lymphoid lineage impairment
22. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020]
23. Italian cystic fibrosis registry (ICFR): Report 2017-2018
24. Shwachman–Diamond syndrome
25. The isochromosome i(7)(q10) carrying c.258+2t>c mutation of the SBDS gene does not promote development of myeloid malignancies in patients with Shwachman syndrome
26. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis
27. Microarray expression studies on bone marrow of patients with Shwachman-Diamond syndrome in relation to deletion of the long arm of chromosome 20, other chromosome anomalies or normal karyotype
28. P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group
29. SPINK1 MUTATION N34S INCREASES RISK OF PANCREATITIS IN PATIENTS WITH CF AND CFTR-RELATED DISORDERS: 489★
30. Expansion and functional characterization of mesenchymal stem cells derived from patients affected by Shwachman-Diamond syndrome: P1005
31. WS06.4 Early Pseudomonas aeruginosa (Pa) isolation impacts on N2-Multiple Breath Washout (MBW) and body mass index (BMI) percentile in children with cystic fibrosis
32. P183 Increase of HLA-G in plasma of cystic fibrosis paediatric patients treated with Docosahexaenoic acid (DHA)
33. WS04.2 Electronic nose (E-nose) analysis of systemic volatile organic compounds (VOCs) pattern distinguishes paediatric patients with cystic fibrosis (CF) from healthy controls (HC) and depicts disease status
34. P007 Functional characterisation of c.1584+18672bpA>G/2183AA>G CFTR variant in rectal organoids
35. WS21.5 Response to ivacaftor of the rare CFTR variants W57G and A234D in intestinal organoids and Fisher Rat Tyroid (FRT) cells
36. P031 What is the role of sweat ions ratio in the diagnosis of cystic fibrosis?
37. Celiac disease and obesity: need for nutritional follow-up after diagnosis
38. Up-regulation of miR-34a-3p and miR-744-3p is associated with down-regulation of PTEN in lymphoblastoid cells from Shwachman-Diamond Syndrome patients
39. Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016
40. Shwachman-Diamond Syndrome: Clinical Phenotypes
41. Energy and micronutrient intakes in a group of children with severe developmental disabilities on home enteral nutrition
42. Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability
43. Gluten sensitivity and ‘normal’ histology: is the intestinal mucosa really normal?
44. Mesenchymal stromal cells from Shwachman-Diamond syndrome patients fail to recreate a bone marrow niche in vivo and exhibit impaired angiogenesis
45. Ataluren-driven restoration of Shwachman-Bodian-Diamond syndrome protein function in Shwachman-Diamond syndrome bone marrow cells
46. P105 The growth in children with Celiac disease after the gluten free diet: a comparison between Italian and American children
47. IPD2.07 Retrospective observational study in cystic fibrosis patients homozygous for F508del treated with lumacaftor/ivacaftor in a compassionate use programme
48. E, Danesino C, Pasquali F, Nicolis E, Cesaro S, Perobelli S. The Italian SDS registry (RI-SDS): evolution form 1999.Proceedings of 8th International Congress on Shwachman-Diamond Syndrome, page 44. Verona 17-20 April 2016
49. Long-term survival probability in Shwachman-Diamond syndrome in italian patients
50. Il trapianto allogenico nei pazienti con Sindrome di Shwachman-Diamond: risultati dell’analisi del registro europeo. XLI Annual Congress of AIEOP (Italian Association of Pediatric Hematology Oncology)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.